CONCLUSIONS
Adjusted indirect comparisons based on currently available
randomised controlled trials suggested that patients
treated with dexlansoprazole 30 mg would have higher
rate with significant difference of symptom control than
esomeprazole 20 mg or 40 mg in the management of
NERD at 4 weeks, although there were no statistically
significant differences between dexlansoprazole and
esomeprazole in other outcomes for the treatment and
maintenance of healed EO. However, these study findings
need to be interpreted with caution due to small
number of studies and other limitations.